title: Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women.
abstract: Human papillomavirus (HPV) DNA testing can be used to identify women at risk of the development of cervical cancer. The cost-effectiveness of HPV screening is dependent on the type-specific HPV prevalence in the general population. The present study describes the prevalence and spectrum of high-risk HPV types found in a large real-life population-based HPV screening trial undertaken entirely within the cervical screening program offered to middle-aged Swedish women. Cervical brush samples from 6,123 women aged 32-38 years were analyzed using a general HPV primer (GP5+/6+) polymerase chain reaction-enzyme immunoassay (PCR-EIA) combined with reverse dot-blot hybridization for confirmation and HPV typing by a single assay. In this study, 6.8% (95% CI 6.2-7.5) (417/6,123) were confirmed as high-risk HPV positive. Infections with 13 different high-risk HPV types were detected, of which HPV 16 was the most prevalent type (2.1%; 128/6,123), followed by HPV 31 (1.1%; 67/6,123). Any one of the HPV types 18, 33, 35, 39, 45, 51, 52, 56, 58, 59, or 66 was detected in 3.6% (223/6,123) of the women. Infection with two, three, and five types simultaneously was identified in 32, 5, and 1 women, respectively. The combination of PCR-EIA as a screening test and reverse dot-blot hybridization as a confirmatory test, was found to be readily applicable to a real-life population-based cervical screening. The type-specific HPV prevalence found support in previous modeling studies suggesting that HPV screening may be a favorable cervical screening strategy.
authors.affiliation: Department of Medical Microbiology, Lund University, University Hospital, Malmö, Sweden. ola.forslund@mikrobiol.mas.lu.se
authors.forename: Ola
authors.initials: O
authors.lastname: Forslund
authors.forename: Annika
authors.initials: A
authors.lastname: Antonsson
authors.forename: Karin
authors.initials: K
authors.lastname: Edlund
authors.forename: Adrian J C
authors.initials: AJ
authors.lastname: van den Brule
authors.forename: Bengt-Göran
authors.initials: BG
authors.lastname: Hansson
authors.forename: Chris J L M
authors.initials: CJ
authors.lastname: Meijer
authors.forename: Walter
authors.initials: W
authors.lastname: Ryd
authors.forename: Eva
authors.initials: E
authors.lastname: Rylander
authors.forename: Anders
authors.initials: A
authors.lastname: Strand
authors.forename: Göran
authors.initials: G
authors.lastname: Wadell
authors.forename: Joakim
authors.initials: J
authors.lastname: Dillner
authors.forename: Bo
authors.initials: B
authors.lastname: Johansson
mesh_terms: D000328:Adult; D002584:Cervix Uteri / Q000821:virology; D005260:Female; D006801:Humans; D015151:Immunoblotting; D007124:Immunoenzyme Techniques; D008403:Mass Screening; D027383:Papillomaviridae / Q000145:classification / Q000235:genetics* / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000453:epidemiology* / Q000821:virology; D016133:Polymerase Chain Reaction; D011159:Population Surveillance; D015995:Prevalence; D013548:Sweden / Q000453:epidemiology; D014412:Tumor Virus Infections / Q000453:epidemiology* / Q000821:virology